SAB BIOTHERAPEUTICS, INC. Accrued Vacation, Current
SAB BIOTHERAPEUTICS, INC. (SABS) had Accrued Vacation, Current of $656.13 thousand as of 2023-12-31, per its 10-K filed 2024-03-29.
Discontinued › Notes › Accrued Liabilities, Current › Employee-related Liabilities, Current
us-gaap:AccruedVacationCurrent · last filed 2024-03-29
- 2023-12-31: Accrued Vacation, Current $656.13K.
- 2023-09-30: Accrued Vacation, Current $694.24K.
- 2023-06-30: Accrued Vacation, Current $648.91K.
- 2023-03-31: Accrued Vacation, Current $609.56K.
| Period end | Accrued Vacation, Current |
|---|---|
| 2023-12-31 | $656.13K 10-K · filed 2024-03-29 |
| 2023-09-30 | $694.24K 10-Q · filed 2023-11-13 |
| 2023-06-30 | $648.91K 10-Q · filed 2023-08-21 |
| 2023-03-31 | $609.56K 10-Q · filed 2023-05-15 |
| 2022-12-31 | $511.85K 10-K · filed 2024-03-29 |
| 2022-09-30 | $563.73K 10-Q · filed 2022-11-14 |
| 2022-06-30 | $626.04K 10-Q · filed 2022-08-10 |
| 2022-03-31 | $678.86K 10-Q · filed 2022-05-12 |
| 2021-12-31 | $552.63K 10-K/A · filed 2023-04-28 |
| 2020-12-31 | $438.94K 10-K/A · filed 2023-04-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |